title: Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.
abstract: The effects of Viloxazine (VLX, 100 mg b.i.d. for 10 days) on the steady-state plasma concentrations of Oxcarbazepine (OXC), its active metabolite 10, 11-dihydro-10-hydroxy-carbazepine (MHD) and the corresponding diol (DHD) were studied in a randomized, double-blind cross-over placebo-controlled trial in 6 epileptic patients stabilized on a fixed dosage of OXC. Administration of VLX resulted in an 11% increase in the plasma concentration of MHD (p = 0.003) associated with a 31% fall in DHD levels (p = 0.0001). Plasma concentrations of unchanged OXC were unaffected by VLX. No changes in seizure frequency nor signs of drug toxicity were observed during the study. Although VLX may inhibit the conversion of MHD to the inactive diol, the interaction is unlikely to be of clinical significance.
authors: Institute of Neurological and Neurosurgical Sciences, University of Messina, Italy.
authors: F
authors: F
authors: Pisani
authors: A
authors: A
authors: Fazio
authors: G
authors: G
authors: Oteri
authors: C
authors: C
authors: Artesi
authors: B
authors: B
authors: Xiao
authors: E
authors: E
authors: Perucca
authors: R
authors: R
authors: Di Perri
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002220:Carbamazepine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D018592:Cross-Over Studies; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D004828:Epilepsies, Partial / Q000097:blood / Q000188:drug therapy; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D017029:Epilepsy, Complex Partial / Q000097:blood / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008875:Middle Aged; D000078330:Oxcarbazepine; D014745:Viloxazine / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: C039775:10,11-dihydro-10-hydroxycarbamazepine; D000927:Anticonvulsants; D002220:Carbamazepine; D014745:Viloxazine; D000078330:Oxcarbazepine